

Big pharma perspective on adaptive clinical trial designs

Boehringer-Ingelheim, Grünenthal and AstraZeneca to discuss company approach to applied clinical trials.

LONDON, ENGLAND, UNITED KINGDOM, January 23, 2017 /EINPresswire.com/ -- As the pharmaceutical industry continues to develop and strengthen adaptive designed approaches to clinical trials, big pharmaceutical companies are setting the standard for successful results. SMi Group has confirmed [three key case studies](#) from three leading companies pioneering innovation at the [9th Adaptive Designs in Clinical Trials](#) conference, which takes place on the 3rd and 4th April 2017.

CASE STUDY #1:

Hot topics and case studies in adaptive designs from a company's perspective

Frank Fleischer, Principal Methodology Statistician at Boehringer-Ingelheim will explore current trends towards adaptive platform based approaches in oncology dose finding as well as adaptive designs in the biosimilar framework. He will also discuss statistical Go's and No Go's as well as alternative development pathway.

CASE STUDY #2:

Adaptive aspects in clinical development in Grünenthal

Grünenthal Head of Biostatistics Cécile Doboïs will highlight cases studies of trials with adaptive designs within the company, focusing on single trials with adaptive design vs the adaptive nature of clinical development programs. Another focus will be the adaptive trial design aspects specific to indicating pain and drug class opioids.

CASE STUDY #3:

Building an adaptive design capability in early development

James Matcham, head of Biometrics for Early Clinical Development at AstraZeneca highlights the company's journey towards building skills and confidence in designing adaptive clinical trials. He will also address and explore opportunities for the implications for early phase decision making.



The 9th Adaptive Designs in Clinical Trials will also feature presentations that will discuss and deliberate key themes such as new approaches in adaptive designs, clinical strategies, optimising drug development in key therapy areas and industry-led approaches to clinical trial success. A detailed agenda is available to view on www.adaptivedesigns.co.uk/EIN.

The event will also feature a post-conference workshop on writing clinical trial simulators hosted by Berry Consultants.

For more details about the conference and registration information, visit www.adaptivedesigns.co.uk/EIN.

ADAPTIVE DESIGNS IN CLINICAL TRIALS
3rd & 4th APRIL 2017
Cophorne Tara Hotel, Kensington, London, UK
www.adaptivedesigns.co.uk/EIN

---end---

Contact Information:

For sponsorship and exhibition queries please contact Alia Malick at amalick@smi-online.co.uk. For delegate queries please contact Fateja Begum at fbegum@smi-online.co.uk. For media queries please contact Honey de Gracia at hdegracia@smi-online.co.uk.

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Honey de Gracia
SMi Group Ltd
+44 (0)20 7827 6102
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.